Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Purchases $19,971.35 in Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Michael Catelani acquired 9,289 shares of Anixa Biosciences stock in a transaction on Wednesday, January 15th. The shares were bought at an average price of $2.15 per share, for a total transaction of $19,971.35. Following the purchase, the chief financial officer now owns 44,500 shares of the company’s stock, valued at $95,675. This represents a 26.38 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Anixa Biosciences Price Performance

Shares of Anixa Biosciences stock opened at $2.41 on Friday. Anixa Biosciences, Inc. has a 1-year low of $2.07 and a 1-year high of $5.13. The company has a market capitalization of $77.59 million, a PE ratio of -6.18 and a beta of 0.90. The business has a 50-day moving average of $2.80 and a 200-day moving average of $3.02.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. On average, equities analysts expect that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current fiscal year.

Institutional Trading of Anixa Biosciences

A number of hedge funds have recently made changes to their positions in ANIX. Concorde Asset Management LLC bought a new position in Anixa Biosciences during the 2nd quarter valued at $31,000. Virtu Financial LLC acquired a new stake in shares of Anixa Biosciences in the 3rd quarter valued at about $34,000. Westside Investment Management Inc. raised its stake in shares of Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares in the last quarter. Tyler Stone Wealth Management lifted its position in shares of Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after purchasing an additional 21,008 shares during the last quarter. Finally, International Assets Investment Management LLC increased its holdings in Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after buying an additional 23,800 shares during the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.

Analyst Upgrades and Downgrades

ANIX has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a report on Tuesday, November 19th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research note on Tuesday.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.